Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Judgement Proof.com who wrote (303)	8/12/1999 1:36:00 PM
From: Skywatcher	Respond to of 1137

I think 1 1/2 is a fine net...netted ABMC again at 1 3/8... think we need some more news about overseas markets from SCLN though. can't beat that 25% per quarter...that I like. Sold some of my shares at 1 3/4...about 25%...so looking to by them back. chris

To: Judgement Proof.com who wrote (303)	8/16/1999 11:25:00 AM
From: Skywatcher	Respond to of 1137

SciClone's ZADAXIN(R), for Treatment of Hepatitis B, Approved In Brunei & Sri Lanka SAN MATEO, Calif., Aug. 16 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN - news) today reported that the Company has received approval to market ZADAXIN® in Brunei and Sri Lanka for treatment of hepatitis B. The Company has received 6 new ZADAXIN marketing approvals in 1999. ZADAXIN has now been approved for marketing in 16 countries, including China, Italy and Mexico. SciClone has filed for approval to market ZADAXIN in 19 additional countries. ZADAXIN, a drug that boosts the immune system without any serious side effects, is prescribed for treatment of hepatitis B as a safer single-agent therapy than the alpha interferons. In addition, ZADAXIN has shown utility and safety when combined with interferon and lamivudine in the treatment of hepatitis B. Phase 3 studies of ZADAXIN in hepatitis B and Phase 2 studies in hepatitis C are being conducted in Japan by Schering-Plough K.K., SciClone's exclusive partner in that market. Hepatitis B is a highly infectious liver disease that can lead to liver cancer and death. Worldwide, there are approximately 350 million long-term carriers of the hepatitis B virus, including 1.2 million in the United States. Well...looks like we added TWO more nations...really one since Brunei is just about the smallest blip on the international radar other than Kuwait...but both are about the richest countries per capita in the world. chris

To: Judgement Proof.com who wrote (303)	8/26/1999 11:53:00 AM
From: Skywatcher	Read Replies (1) \| Respond to of 1137

Looks like they are getting more confident and aggressive...I like it. SciClone Acquires New Class of Immunomodulators Potential Orally Active Compounds Covered by New U.S. Patent SAN MATEO, Calif., Aug. 26 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN - news) today reported that the Company has exclusively licensed a unique new class of compounds which boost the immune system. A recently issued United States Patent covers the composition of matter of these compounds as well as their therapeutic use as immunomodulators. In preclinical studies, the compounds stimulated the immune system in a manner similar to SciClone's lead drug, ZADAXIN®, an injectable drug currently used to fight hepatitis B, hepatitis C and multiple types of cancer. At least one compound in the class, SCV-07, has the potential to be orally active. SciClone licensed the class of compounds from Edward T. Wei, Ph.D. of the University of California, Berkeley. ''We have initially selected SCV-07 for further development as a new generation ZADAXIN. SCV-07 stimulates the immune system, may be orally active and is covered by a new patent,'' said Donald R. Sellers, SciClone's President and Chief Executive Officer. ''We have a growing global position in immunotherapeutics. We intend to leverage this position by adding novel compounds like SCV-07 to our pipeline targeting cancer, infectious diseases and cystic fibrosis.'' So putting some of the 25% growth in revenues to use seems like the management is becoming more confident and perhaps they are setting the stage for some more moves into the US market. chris

To: Judgement Proof.com who wrote (303)	9/21/1999 11:33:00 AM
From: Skywatcher	Read Replies (1) \| Respond to of 1137

SciClone Receives U.S. Patent for Combination Therapy of ZADAXIN(R) Plus Famciclovir for Treatment of Hepatitis B SAN MATEO, Calif., Sept. 21 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN - news) today announced that the U.S. Patent and Trademark Office has granted another U.S. patent covering the use of the Company's lead drug, ZADAXIN, for treatment of hepatitis B. ZADAXIN, a drug that boosts the immune system without any serious side effects, has been approved for marketing in 16 countries worldwide, principally as a treatment for hepatitis B and hepatitis C. ''Accumulating clinical data indicate ZADAXIN's potential synergy with nucleoside analogues, suggesting that combination therapy may be a future approach to treat hepatitis B, as it is for AIDS and hepatitis C,'' said Alfred R. Rudolph, M.D., SciClone's Chief Operating Officer. ''The ideal combination therapy for hepatitis B will simultaneously suppress viral replication and boost the patient's immune system to attack and destroy virus-infected liver cells. Nucleoside analogues such as famciclovir and lamivudine suppress viral replication while ZADAXIN boosts the immune system.'' Hepatitis B is a highly infectious liver disease and one of the most common causes of death in the world. Worldwide, there are approximately 350 million long-term carriers of the hepatitis B virus, including over one million in the U.S. These carriers of the hepatitis B virus have a 200-fold increased chance of developing serious liver disease, including liver cancer, the most common cancer in the world, and cirrhosis. THIS IS CONTINUED GOOD NEWS...Stock could still use an infusion of excitement, but this will do for today chris